ArticleThe Journal of infection2021
Early administration of ritonavir-boosted lopinavir could prevent severe COVID-19.
Article in The Journal of infection, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it, 17 citations in OpenAlex.
- Systematic Review and Patient-Level Meta-Analysis of SARS-CoV-2 Viral Dynamics to Model Response to Antiviral Therapies.Clinical pharmacology and therapeutics · 2021Pooled it
- Article
- Screening compounds for treating the diabetes and COVID-19 from Miao medicine by molecular docking and bioinformatics.Arabian journal of chemistry · 2023Article
- Post-COVID-19 syndrome. SARS-CoV-2 RNA detection in plasma, stool, and urine in patients with persistent symptoms after COVID-19.BMC infectious diseases · 2022Article
- Early Lopinavir/ritonavir does not reduce mortality in COVID-19 patients: Results of a large multicenter study.The Journal of infection · 2021Article
- Antiretrovirals for Prophylaxis Against COVID-19: A Comprehensive Literature Review.Journal of clinical pharmacology · 2021Review
- Lopinavir/ritonavir: Repurposing an old drug for HIV infection in COVID-19 treatment.Biomedical journal · 2021Review
- Knowledge, Attitude, Behavior, and Socioeconomic Conditions of People Living with HIV in Indonesia During the COVID-19 Pandemic: A Cross-Sectional Study.HIV/AIDS (Auckland, N.Z.) · 2021Article
- Effectiveness of early treatment of lopinavir-ritonavir in patients with severe COVID-19: a case series.Clinical medicine (London, England) · 2021Article
- Efficacy and Safety of Lopinavir/Ritonavir for Treatment of COVID-19: A Systematic Review and Meta-Analysis.Tropical medicine and infectious disease · 2020Review
- Approaching coronavirus disease 2019: Mechanisms of action of repurposed drugs with potential activity against SARS-CoV-2.Biochemical pharmacology · 2020Review
Corrections and comments
- Commented on by
- Comment on
Authors and funding
11 authors at 6 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.